Development of therapeutic medical countermeasures for biodefense and emerging infectious diseases

Ended Definitive Contract Awarded Last action

Contract number
HHSN272201300019C
Awardee
Awarding agency
Obligated
$28,199,896

Award facts

Opportunity
Contract value 100% obligated
$28,199,895.53 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
28 offers Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Malvern, PA 19355, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00025 -$0
Funding Only Action P00024 -$0
Funding Only Action P00023 -$25,468
Other Administrative Action P00022 $0
Other Administrative Action 21 $0
Supplemental Agreement for work within scope 20 $1,324,969
Other Administrative Action 19 $0
Supplemental Agreement for work within scope 18 $1,264,512
Exercise an Option 17 $1,525,702
Supplemental Agreement for work within scope 16 $2,821,058
Supplemental Agreement for work within scope 15 -$1,965,989
Other Administrative Action 14 $0
Exercise an Option 13 $1,965,989
Supplemental Agreement for work within scope 12 $1,247,892
Other Administrative Action 11 $3,557,446
Other Administrative Action 10 -$3,557,446
Exercise an Option 9 $3,596,319
Other Administrative Action 8 $0
Other Administrative Action 7 · Fcoi and extend time of option $0
Exercise an Option 6 $2,857,938
Funding Only Action 5 $1,200,000
Exercise an Option 4 $4,203,649
Change Order 3 $1,100,000
Exercise an Option 2 $1,695,476
Funding Only Action 1 $280,152
Original award $5,107,697
Show all 26

About this award

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $28.2 million definitive contract to Venatorx Pharmaceuticals Inc. for development of therapeutic medical countermeasures for biodefense and emerging infectious diseases on September 16, 2013, under cost-plus-fixed-fee pricing with no set-aside.

Place of performance is Malvern, Pennsylvania. The contract ceiling is $28,199,895.53 with an ultimate completion date of September 30, 2019.

Quick answers

Who was awarded contract HHSN272201300019C?

HHSN272201300019C was awarded to Venatorx Pharmaceuticals Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 16, 2013.

How much is contract HHSN272201300019C worth?

The government has obligated $28,199,896 on HHSN272201300019C.

Was contract HHSN272201300019C competed?

The government received 28 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award